

Discover why MetaVia Inc. (NASDAQ: MTVA) stock is surging on Friday following new peer-reviewed data on its MASH treatment, reversing Thursday's dip.
You can purchase shares of MetaVia (NASDAQ:MTVA) through any online brokerage.
Other companies in MetaVia’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
MetaVia has a consensus price target of $61.67.
The stock price for MetaVia (NASDAQ: MTVA) is $1.39 last updated October 23, 2026 at 5:00 AM EDT.
There are no upcoming dividends for MetaVia.
MetaVia does not have any upcoming earnings scheduled.
There is no upcoming split for MetaVia.
MetaVia is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity....